Mallinckrodt : Discusses Pipeline Transformation, Company Outlook at Investor Briefing
Release date- 05102017 - STAINES -
The event will highlight how Mallinckrodt's ongoing portfolio transformation has enhanced financial strength and broadened future opportunities, providing long-term value for patients and shareholders.
At the briefing, members of the company's management team and medical experts, both internal and external, will share insights on a number of topics, including:
Development pipeline highlights:
Updates on the company's broad spectrum of near- and longer-term developmental programs for inline and investigational assets, including clinical and health economic data
Aggregate net sales expectations for near-term development programs, the sum of which is expected to exceed
Pipeline expected to contribute >20% of total growth long term Four product launches expected over next three years Scientific poster presentations on key development products and Product demonstrations of the INOMAX and
Those unable to attend the briefing in person can view a live webcast of the presentations and Q&A session at Mallinckrodt's Investor Relations website, linked here, beginning at
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the
Cautionary Statements Related to Forward Looking Statements
Statements in this document that are not strictly historical, including statements regarding future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting Mallinckrodt's businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be 'forward-looking' statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties.
There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: general economic conditions and conditions affecting the industries in which Mallinckrodt operates; the commercial success of Mallinckrodt'sproducts; Mallinckrodt's ability to realize anticipated growth, synergies and cost savings from transactions; conditions that could necessitate an evaluation of Mallinckrodt's goodwill and/or intangible assets for possible impairment; changes in laws and regulations; Mallinckrodt's ability to successfully integrate acquisitions of operations, technology, products and businesses generally and to realize anticipated growth, synergies and cost savings; Mallinckrodt's ability to successfully develop or commercialize new products; Mallinckrodt's ability to protect intellectual property rights; Mallinckrodt's ability to receive procurement and production quotas granted by the
These and other factors are identified and described in more detail in the 'Risk Factors' sections of Mallinckrodt'sAnnual Report on Form 10-K for the fiscal year ended
Email: [email protected]
(c) 2017 Electronic News Publishing -, source